[1]高洪元,张玺炜,汪洋,等.TERTp和1p/19q对顺铂联合替莫唑胺同期放化疗治疗MGMT启动子未甲基化GBM的预后影响[J].临床神经外科杂志,2019,16(4):289-293.[doi:10.3969/j.issn.1672-7770.2019.04.003]
 GAO Hong-yuan,ZHANG Xi-wei,WANG Yang,et al.Prognostic value of TERTp and 1p/19q in cisplatin combined with temozolomide concurrent chemoradiotherapy for newly diagnosed GBM with unmethylated MGMT promoter[J].Journal of Clinical Neurosurgery,2019,16(4):289-293.[doi:10.3969/j.issn.1672-7770.2019.04.003]
点击复制

TERTp和1p/19q对顺铂联合替莫唑胺同期放化疗治疗MGMT启动子未甲基化GBM的预后影响()
分享到:

《临床神经外科杂志》[ISSN:1672-7770/CN:32-1727/R]

卷:
16
期数:
2019年第4期
页码:
289-293
栏目:
胶质瘤基础研究专题
出版日期:
2019-08-15

文章信息/Info

Title:
Prognostic value of TERTp and 1p/19q in cisplatin combined with temozolomide concurrent chemoradiotherapy for newly diagnosed GBM with unmethylated MGMT promoter
作者:
高洪元张玺炜汪洋盛晓芳吴学勇殷晓峰陈淑倪春霞孟歌胡莉王宝红
200040上海,上海市静安区中心医院(复旦大学附属华山医院静安分院)肿瘤科(高洪元,张玺炜,汪洋,盛晓芳,吴学勇,殷晓峰);复旦大学附属华山医院上海伽玛医院放疗中心(汪洋,盛晓芳,陈淑,倪春霞,孟歌,胡莉,王宝红)
Author(s):
GAO Hong-yuan ZHANG Xi-wei WANG Yang et al.
Department of Oncology, Jing’an District Central Hospital, Huashan Hospital, Fudan University, Shanghai 200040, China
关键词:
胶质母细胞瘤O6-甲基鸟嘌呤-DNA甲基转移酶启动子未甲基化端粒酶逆转录酶1p/19q顺铂替莫唑胺
Keywords:
glioblastoma unmethylated MGMT promoter TERT 1p/19q cisplatin temozolomide
分类号:
R739.41
DOI:
10.3969/j.issn.1672-7770.2019.04.003
文献标志码:
A
摘要:
【摘要】目的 探讨TERTp和1p/19q不同表型对DDP联合TMZ同期放化疗治疗新诊断 MGMT启动子未甲基化GBM的预后影响。方法回顾性分析73例新诊断MGMT启动子未甲基化的GBM的临床资料,均接受DDP联合TMZ同期放化疗,行TERTp和1p/19q检测,分析TERTp和1p/19q不同表型的临床特征、副反应、PFS和OS。结果根据TERTp分为 TERTp wt 30例和TERTp mut 43例,根据1p/19q分为无缺失组62例和缺失组11例,临床资料差异均无统计学意义(P>0.05)。截至2019年1月31日,44例复发,其中TERTp wt 17例、TERTp mut 27例,中位PFS为12.0个月和10.0个月,1年PFS率为33.6%和27.2%。22例死亡,其中TERTp wt 9例、TERTp mut 13例,中位OS为20.0个月和19.0个月,1年OS率为77.9%和73.2%,差异无统计学意义。1p/19q无缺失组复发38例,缺失组复发6例,中位PFS为10.0个月与22.0个月,1年PFS率为20.4%和60.0%,差异无统计学意义。1p/19q无缺失组死亡19例,缺失组死亡3例,中位OS为18.0个月和23.0个月;1年OS率为60.3%和88.9%。1p/19q缺失组疗效有高于无缺失组的趋势,但差异无统计学意义。结论DDP联合TMZ同期放化疗治疗MGMT启动子未甲基化新诊断GBM,TERTp wt疗效略高于TERTp mut,1p/19q缺失组疗效有高于无缺失组的趋势,但差异未达到统计学意义。1p/19q可能在MGMT启动子未甲基化新诊断GBM接受DDP联合TMZ同期放化疗中有潜在的影响预后价值,值得进一步研究。
Abstract:
Abstract:ObjectiveTo investigate the clinical characteristics and prognostic value of TERTp and 1p/19q phenotype in DDP+TMZ concurrent chemoradiotherapy for newly diagnosed GBM with unmethylated MGMT promoter. MethodsA retrospective analysis was made in 73 newly diagnosed GBM with unmethylated MGMT promoter. All patients received DDP+TMZ. The aim of this study was to analyze the clinical characteristics, adverse reactions, PFS and OS of patients with different TERTp and 1p/19q groups. ResultsAccording to TERTp, there were 30 cases of TERTp wt and 43 cases of TERTp mut. According to 1p/19q, 62 cases were non-deletion and 11 cases were deletion. There was no significant difference in clinical parameters between two groups(P>0.05). Up to 31st January 2019, 44 patients had recurrence, 17 with TERTp wt and 27 with TERTp mut. The median PFS was 12.0 and 10.0 months, respectively. The 1-year PFS rate was 33.6% and 27.2%. 22 patients died, 9 with TERTp wt and 13 with TERTp mut. The median OS was 20.0 and 19.0 months. The 1-year OS rate was 77.9% and 73.2%. There were 38 recurrences in 1p/19q non-deletion and 6 recurrences in deletion. The median PFS was 10.0 and 22.0 months respectively. The 1-year PFS rate was 20.4% and 60.0%. There were 19 deaths with 1p/19q non-deletion, 3 deaths in deletion, and the median OS was 18.0 and 23.0 months. The 1-year OS rates were 60.3% and 88.9%. There was a better trend in the efficacy for 1p/19q non-deletion than that of deletion. But the difference was not significant. ConclusionThe efficacy of TERTp wt is slightly higher than that of TERTp mut. The efficacy of 1p/19q deletion group is higher than that of non-deletion, but the difference is not statistically significant. 1p/19q may have potential prognostic value in newly diagnosed GBM with unmethylated MGMT promoter receiving DDP +TMZ concurrent chemoradiotherapy, which deserves further study.

相似文献/References:

[1]刘翔宇,孙康健,王汉东,等.荧光实时监测贝伐单抗治疗胶质母细胞移植瘤的实验研究[J].临床神经外科杂志,2016,(02):110.
 LIU Xiang-yu,SUN Kang-jian,WANG Han-dong,et al.Bioluminescent imaging of the impact of bevacizumab on anti-proliferation and angiogenesis in human glioblastomaxenografts in vivo[J].Journal of Clinical Neurosurgery,2016,(4):110.
[2]王天伟,牛小东,毛庆.《艾滋病合并胶质瘤2例报告及文献复习》[J].临床神经外科杂志,2017,14(02):91.
 WANG Tian-wei,NIU Xiao-dong,MAO Qing..Glioblastoma in patient with AIDS:two cases report and review of literatures[J].Journal of Clinical Neurosurgery,2017,14(4):91.
[3]李凌,黄红星,邹叔骋,等.以癫痫为首发症状的胶质母细胞瘤预后影响因素分析[J].临床神经外科杂志,2018,15(03):170.
 LI Ling,HUANG Hong-xing,ZOU Shu-cheng,et al.Prognostic factors of glioblastoma presenting with epilepsy as a primary symptom[J].Journal of Clinical Neurosurgery,2018,15(4):170.
[4]李焦明,甘有均,牛小东,等.不典型胶质母细胞瘤误诊为脑包虫病1例报告及文献复习[J].临床神经外科杂志,2018,15(05):384.[doi:10.3969/j.issn.1672-7770.2018.05.016]
 LI Jiao-ming,GAN You-jun,NIU Xiao-dong,et al.Atypical glioblastoma misdiagnosed as echinococcosis(a report of 1 case and review of literature)[J].Journal of Clinical Neurosurgery,2018,15(4):384.[doi:10.3969/j.issn.1672-7770.2018.05.016]
[5]倪春霞,张玺炜,汪洋,等.顺铂联合替莫唑胺放化疗治疗MGMT启动子未甲基化胶质母细胞瘤的初步研究[J].临床神经外科杂志,2019,16(1):6.[doi:10.3969/j.issn.1672-7770.2019.01.002]
 NI Chun-xia,ZHANG Xi-wei,WANG Yang,et al.Randomized controlled trial design and analysis of preliminary result on cisplatin combined with radiotherapy and concurrent chemotherapy of Temozolomide in MGMT unmethylated glioblastomas[J].Journal of Clinical Neurosurgery,2019,16(4):6.[doi:10.3969/j.issn.1672-7770.2019.01.002]
[6]李顺,邱娜,叶成坤,等.MRI纹理分析在脑脓肿与胶质母细胞瘤鉴别诊断中的应用价值[J].临床神经外科杂志,2019,16(3):245.[doi:10.3969/j.issn.1672-7770.2019.03.013]
 LI Shun,QIU Na,YE Cheng-kun,et al.MRI texture analysis on differential diagnosis of brain abscess and glioblastoma[J].Journal of Clinical Neurosurgery,2019,16(4):245.[doi:10.3969/j.issn.1672-7770.2019.03.013]

更新日期/Last Update: 2019-08-01